期刊文献+

宫颈癌组织和Hela细胞中miR-664的表达及其对顺铂化疗敏感性的影响 被引量:6

Expression of miR-664 in cervical cancer tissues and Hela cells and its effect on chemosensitivity to cisplatin
下载PDF
导出
摘要 目的:探讨miR-664在宫颈癌组织和Hela细胞中的表达及其对顺铂化疗敏感性的影响。方法:采用RTPCR法检测142例宫颈癌组织及相应癌旁组织标本miR-664的表达,分析其表达与患者临床病理参数的关系。将宫颈癌Hela-229细胞分为3组:对照组、顺铂组、顺铂+转染组。其中,顺铂+转染组细胞转染miR-664拟似物。细胞培养结束后,采用MTT法检测各组细胞活力、镜下观察单克隆形成数目,流式细胞术检测细胞凋亡率、G_1期细胞比例,Transwell细胞迁移实验测定穿膜细胞数,RT-PCR法检测细胞miR-664表达水平,ELISA法检测细胞培养液中的Caspase-3、Caspase-9浓度。结果:(1)宫颈癌组织miR-664表达水平明显低于癌旁组织(P <0.01); TNM分期越高、病理学分期越高、有复发、有淋巴结转移的病例,miR-664阳性表达率明显下降(均P <0.01);(2)体外细胞实验中,顺铂组、顺铂+转染组细胞存活率、单克隆形成数目、G_1期细胞数、细胞穿膜数均明显低于对照组(均P <0.01),细胞凋亡率、Caspase-3、Caspase-9浓度、miR-664表达显著高于对照组(P <0.01);顺铂+转染组存活率、单克隆形成数目、G_1期细胞比率、细胞穿膜数明显低于顺铂组(均P <0.01),细胞凋亡率、Caspase-3、Caspase-9浓度、miR-664表达显著高于顺铂组(均P <0.01)。结论:miR-664在宫颈癌组织中表达降低; miR-664通过诱导Caspase-3、Caspase-9过表达,进而抑制宫颈癌细胞株的增殖、迁移、浸润,增强宫颈癌细胞对顺铂化疗的敏感性。 Objective: To investigate the expression levels of miR-664 in cervical cancer tissues and its relationship with chemosensitivity to cisplatin in Hela cells. Methods: The expression of miR-664 in 142 cervical cancer tissues and corresponding adjacent tissues was detected by RT-PCR. The relationship between the expression and clinicopathological parameters was analyzed. Cervical cancer Hela-229 cells were divided into three groups: control group,cisplatin group,cisplatin + transfection group. Among them,cisplatin + transfection group cells were transfected with miR-664 mimics. After the end of cell culture,the viability of each group was detected by MTT assay,the number of monoclonal formation was observed under microscope,the apoptosis rate and cell ratio of G1 phase were detected by flow cytometry, and the number of transmembrane cells was determined by Transwell cell migration assay. The level of miR-664 was detected by RT-PCR method,and the concentration of Caspase-3 and Caspase-9 in cell culture medium was detected by ELISA method. Results: The expression level of miR-664 in cervical cancer tissues was significantly lower than that in adjacent tissues ( P < 0. 01). The higher the TNM stage,the higher the pathological stage,the recurrence and lymph node metastasis,the lower the positive expression rate of miR-664( P < 0. 01). In vitro cell experiments,cisplatin group,cisplatin + transfection group cell survival rate,number of monoclonal formation,number of G1 cells,cell permeation number were significantly lower than the control group( P < 0. 01);apoptosis rate,Caspase-3,Caspase-9 concentration, miR-664 expression was significantly higher than the control group ( P < 0. 01);cisplatin + transfection group survival rate,number of monoclonal formation,G1 phase cell ratio,the number of transmembrane cells was significantly lower than that of cisplatin group ( P < 0. 01). The apoptosis rate, Caspase-3,Caspase-9 concentration and miR-664 expression in cisplatin + transfection group were significantly higher than those in cisplatin group( P < 0. 01). Conclusion: miR-664 expression is down-regulated in cervical cancer tissues,while the miR-664 can enhance chemosensitivity to cisplatin,and its mechanism may be related to miR-664 induced overexpression of Caspase-3 and Caspase-9,as well as the inhibition of the proliferation,migration and infiltration of cervical cancer cells.
作者 魏茜雪 秦雪 陈青青 严丽梅 WEI Qian-xue;QIN Xue;CHEN Qing-qing;YAN Li-mei(Department of Gynecology,Shengjing Hospital of China Medical University,Shenyang Liaoning 110004,China)
出处 《江苏大学学报(医学版)》 CAS 2019年第2期147-152,共6页 Journal of Jiangsu University:Medicine Edition
基金 国家自然科学基金资助项目(81602304)
关键词 miR-664 宫颈癌 顺铂 化疗敏感性 miR-664 cervical cancer cisplatin chemosensitivity
  • 相关文献

参考文献2

二级参考文献14

  • 1刘东海,张乐鸣,张顺,毛联钢,冯伟云.乳腺癌患者c-erBb-2基因荧光定量PCR方法的研究[J].中国病理生理杂志,2006,22(2):380-383. 被引量:1
  • 2Ambros V.MicroRNA pathways in flies and worms:growth,death,fat,stress,and timing[J].Cell,2003,113(6):673-676.
  • 3Iorio MV,Ferracin M,Liu CG,et al.MicroRNA gene expression deregulation in human breast cancer[J].Cancer Res,2005,65(16):7065-7070.
  • 4Chan JA,Krichevsky AM,Kosik KS.MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells[J].Cancer Res,2005,65(14):6029-6033.
  • 5Yanaihara N,Caplen N,Bowman E,et al.Unique microRNA molecular profiles in lung cancer diagnosis and prognosis[J].Cancer Cell,2006,9(3):189-198.
  • 6Singletary SE,Allred C,Ashley P,et al.Staging system for breast cancer:revisions for the 6th edition of the AJCC Cancer Staging Manual[J].Surg Clin North Am,2003,83(4):803-819.
  • 7Livak KJ,Schmittgen TD.Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method[J].Methods,2001,25(4):402-408.
  • 8Gramantieri L,Ferracin M,Fornari F,et al.Cyclin G1 is a target of miR-122a,a microRNA frequently down-regulated in human hepatocellular carcinoma[J].Cancer Res,2007,67(13):6092-6099.
  • 9Rhodes A,Jasani B,Anderson E,et al.Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors:a comparative study involving results from laboratories in 21 countries[J].Am J Clin Pathol,2002,118(3):408-417.
  • 10Si ML,Zhu S,Wu H,et al.miR-21-mediated tumor growth[J].Oncogene,2007,26(19):2799-2803.

共引文献17

同被引文献64

引证文献6

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部